Intratumoral immunotherapy prior to cancer surgery, a promising therapeutic approach
Cancer immunotherapy has made astonishing progress in the last 10–15 years, and the rate of progress is accelerating. However, only 20 to 40% of patients benefit from this therapy with most immunotherapy applied post discovery of metastatic disease when therapeutic impact is more difficult to achiev...
Saved in:
| Main Authors: | Kevine Silihe Kamga, Steven Fiering |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2025-06-01
|
| Series: | Frontiers in Immunology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fimmu.2025.1545000/full |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Case Report: Complete response with combination oncolytic virus immunotherapy in a patient with stage IV renal cell carcinoma—a promising innovative approach
by: Benjamin Gesundheit, et al.
Published: (2025-08-01) -
Intratumoral neoadjuvant immunotherapy based on the BO-112 viral RNA mimetic
by: Maite Alvarez, et al.
Published: (2023-12-01) -
Repurposing the yellow fever vaccine for intratumoral immunotherapy
by: Maria Angela Aznar, et al.
Published: (2019-11-01) -
In Situ Tumor Vaccination Using Lipid Nanoparticles to Deliver Interferon-β mRNA Cargo
by: Kenji Kimura, et al.
Published: (2025-02-01) -
Intratumor heterogeneity related signature for clinical outcome and immunotherapy advantages in lung adenocarcinoma
by: Yanhua Zuo, et al.
Published: (2025-03-01)